Telix Pharmaceuticals (TLX) Stock Forecast: StockMap's 2-Week Call

TLX stock forecast: StockMap's model makes no two-week call on Telix Pharmaceuticals after the Nov 19 close: its evidence is split, 5 reasons for and 10 against. Right in 1 of 4 two-week windows on TLX since Aug 21; by chance, a call on the same dates was right 67% of the time.

Telix Pharmaceuticals last closed at $8.71, -2.79% on the session.

Against the IVW growth benchmark the position is -0.46% over the forecast window.

Telix Pharmaceuticals' market cap is $2.96B as of November 19, 2026.

No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -6 (too close to call).

Where TLX sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 5 bullish and 10 bearish.

Agreement across those insights is 67%.

19 daily calls for TLX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

Telix Pharmaceuticals is classified under Health Care / Biotechnology.

StockMap tracks Telix Pharmaceuticals as the 70th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.

On that composite Telix Pharmaceuticals ranks 95th of 394 in the group, against a group median of -0.27.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 19, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Telix Pharmaceuticals (TLX) — StockMap 2-week forecast & tracked accuracy